Indonesian Political, Business & Finance News

Minister of Religious Affairs Mandates Halal Certification for Pharmaceuticals This Year: Industry Response

| | Source: REPUBLIKA Translated from Indonesian | Regulation
Minister of Religious Affairs Mandates Halal Certification for Pharmaceuticals This Year: Industry Response
Image: REPUBLIKA

JAKARTA — Minister of Religious Affairs Prof KH Nasaruddin Umar has reminded industry players and the Indonesian public that all pharmaceutical products must hold halal certification by no later than 17 October 2026. The requirement is mandated under Government Regulation (PP) No. 42 of 2024 as a form of state protection of consumer rights.

He stressed that the deadline applies to various product categories, not only medicines. “The Indonesian government is moving swiftly towards the enforcement of mandatory halal certification, particularly for pharmaceutical products. This is part of protecting consumer rights,” the Minister said in a written statement.

The industry has responded to the Minister’s warning. Pyridam Farma (PYFA), through its subsidiary PT Ethica Industri Farmasi (Ethica Farma), has completed halal certification for its injection and sterile medicine product lines.

PYFA Director Antes Eko Prasetyo affirmed that the move represents the company’s proactive response to complying with Government Regulation No. 42 of 2024 and the directive from the Halal Product Assurance Organising Agency (BPJPH), which stipulates that after 17 October 2026, products must carry the new Indonesian Halal Label.

In a written statement on Monday (23/2/2026), Antes stressed that the company did not wait until the final deadline to comply with the regulation. “We recognise that halal assurance is a crucial aspect for patients in Indonesia. Therefore, we have moved early. This is proof of PYFA’s dedication, particularly Ethica’s, in providing a sense of safety and comfort for the Indonesian public in accessing healthcare services,” he said.

Antes said that support for the halal campaign is not merely about regulatory compliance but is part of the company’s sustainability strategy to enhance the competitiveness of the national and global pharmaceutical industry.

“We hope that Ethica products can be more widely accepted and provide peace of mind for patients,” he added.

View JSON | Print